Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page
- Check4 days agoChange DetectedA site-wide notice about intermittent delays was added. The revision version was updated from v3.6.4 to v3.6.5.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4. This indicates a minor metadata update to the record rather than a substantive change to the study details.SummaryDifference0.1%

- Check33 days agoChange DetectedNo additions or deletions were reported; there are no textual updates to summarize.SummaryDifference0.1%

- Check47 days agoChange DetectedA new revision tag v3.6.3 was added to the page, replacing the previous v3.6.1. This indicates an update to the page's revision history.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.6.1 is now shown instead of v3.6.0, indicating a small page template update rather than substantive changes to the study record. No study data or navigation elements appear to be altered.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page now indicates enrollment is closed to new participants ('No longer looking for participants') and adds new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study). A minor formatting change updates the Intervention/Treatment heading (from 'Intervention / Treatment') and the revision label to v3.6.0.SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.